INSULIN RESISTANCE, METABOLIC STATUS AND RELATION BETWEEN METABOLIC PARAMETERS IN POLYCYSTIC OVARY SYNDROME PATIENTS

Öz

Aim: to investigate the hormonal status, insulin resistance, clinical and metabolic parameters and their correlation in polycystic ovary syndrome PCOS patients. Material And Methods: The study was performed on a total of 81 patients with menstrual irregularity, hirsutism and obesity who were admitted to Zekai Tahir Burak Women’s Health Educational and Research Hospital infertility and adolescent outpatient clinics between August 2010- August 2011. The serum levels of fasting insulin and glucose, 75 g oral glucose tolerance test OGTT , low density lipoproteins LDL , triglyseride TG , high density lipoproteins HDL , 17-hydroxyprogesterone, dehydroepiandrostenedione, androstenedione, total and free testosterone, thyroid stimulan hormon TSH were investigated, and body mass index BMI , homeostasis model assessment of insulin resistance HOMA-IR scores were calculated for all participants. Results: On Body Mass Index BMI match tests; serum levels of fasting glucose, fasting insulin and 2. hour 75 gr OGTT results were significantly higher in patients with BMI>25 n=32 %39,5 p25 n=49 %60,5 serum levels of triglyseride were significantly higher than patients with BMI

Anahtar Kelimeler

• Polycystic over Syndrome,insulin resistance,body mass index

POLİKİSTİK OVER HASTALARINDA İNSULİN DİRENCİ, METABOLİK DURUM VE METABOLİK PARAMETRELER ARASINDAKİ İLİŞKİ

Öz

Amaç: Polikistik over sendromu PCOS tanısı konulmuş bireylerde klinik, metabolik ve hormonal parametreler, insülin direnci araştırması ve birbiri ile ilişkilerini incelemekti. Yöntem ve Gereçler: Ağustos 2010 - ağustos 2011 tarihleri arasında Zekai Tahir Burak Kadın Sağlığı ve Hastalıkları Hastanesi İnfertilite ve Gençlik Merkezi Poliklinikleri’ne adet düzensizliği, tüylenmede artış, obezite şikâyetleri ile başvuran toplam 81 hastada da yapıldı. Tüm hastalarda serum açlık insülin ve glukoz, 75 gr. oral glukoz tolerans test OGTT , düşük dansiteli li- poprotein LDL , trigliserid TG , yüksek dansiteli lipoprotein HDL , 17 hidroksiprogesteron, dehidroepiandrostenedion, androstenedion, total ve serbest testos- teron, tiroid stimulan hormon TSH seviyeleri araştırıldı. Vücut kitle indeksi VKI ve Homeostasis Model Assessment of İnsulin Resistance HOMA-IR skorları hesaplandı. Bulgular: VKI değerlendirmesinde VKI>25 n=32 %39,5 olan hastalarda HOMA-lR skoru, açlık insülin seviyesi ve 2.saat 75 gr OGTT değeri, VKI25 olan gruba göre anlamlı derecede yüksekdi p

Anahtar Kelimeler

• Polikistik over sendrom PCOS,insülin direnci,vücut kitle indeksi

Kaynakça

1. Farah, L., et al., Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med, 1999. 44(10): p. 4.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. (1): p. 41-7.
3. Azziz, R., et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an An- drogen Excess Society guideline. J Clin Endocrinol Metab, 2006. 91(11): p. 4237-45.
4. Barbieri, R.L. and M.D. Hornstein, Hyperinsulinemia and ovarian hy- perandrogenism. Cause and effect. Endocrinol Metab Clin North Am, 17(4): p. 685-703. Arlt, W., R.J. Auchus, and W.L. Miller, Thiazolidinediones but not met- formin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hy- droxysteroid dehydrogenase. J Biol Chem, 2001. 276(20): p. 16767-71.
5. Dunaif, A., et al., Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 1989. 38(9): p. 1165-74.
6. Beamer, B.A., et al., Association of the Pro12Ala variant in the peroxi- some proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes, 1998. 47(11): p. 1806-8.
7. Crave, J.C., et al., Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab, 1995. 80(7): p. 2057-62.
8. De Leo, V., A. la Marca, and F. Petraglia, Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev, 2003. 24(5): p. 67.

9. Poretsky, L., et al., Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin En- docrinol Metab, 1985. 61(4): p. 728-34.
10. Poretsky, L., et al., The insulin-related ovarian regulatory system in health and disease. Endocr Rev, 1999. 20(4): p. 535-82.
11. Azziz, R., Androgen excess is the key element in polycystic ovary syn- drome. Fertil Steril, 2003. 80(2): p. 252-4.
12. Talbott, E., et al., Adverse lipid and coronary heart disease risk pro- files in young women with polycystic ovary syndrome: results of a case- control study. J Clin Epidemiol, 1998. 51(5): p. 415-22.
13. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and In- fertility. Seventh edition. Lippincott Williams and Wilkins Philadelphia p.502-503,471,488-490
14. Balen, A.H., et al., Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod, 1995. 10(8): p. 2107-11.
15. Wild, R.A., Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med, 1995. 98(1A): p. 27S-32S.
16. Conway, G.S., et al., Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf), 1992. 37(2): p. 119-25.
17. Aherne SA. polycystic ovary syndrome.Nursing Standart 18(26):40- , 2004
18. Legro, R.S., Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev, 2003. 24(3): p. 302-12.
19. Kauffman, R.P., et al., Polycystic ovarian syndrome and insulin re- sistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol, 2002. 187(5): p. 1362-9.
20. Gennarelli, G., et al., Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod, 2000. 15(10): p. 2098-102.
21. Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association be- tweenhypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults.Metabolism. 2006 Nov;55(11):1546-50.
22. Panidis, D., et al., Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Delta4- androstenedione. Hum Reprod, 2004. 19(8): p. 1728-33.
23. Stefan, N., et al., Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plas- ma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 2002. 51(6): p. 1884-8.
24. Indhavivadhana, S., et al., Prevalence of metabolic syndrome in repro- ductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thai, 93(6): p. 653-60. Cosar, E., et al., Body fat composition and distribution in women with polycystic ovary syndrome. Gynecol Endocrinol, 2008. 24(8): p. 428-32.
25. Yucel, A., V. Noyan, and N. Sagsoz, The association of serum andro- gens and insulin resistance with fat distribution in polycystic ovary syn- drome. Eur J Obstet Gynecol Reprod Biol, 2006. 126(1): p. 81-6.
26. Rogez, G., et al., Layered hydroxide hybrid nanostructures: a route to multifunctionality. Chem Soc Rev, 2011. 40(2): p. 1031-58.